Plain English Summary
Background and study aims
Obstructive sleep apnea (OSA) occurs in up to 10% of the general population and is characterised by repetitive pauses of breathing during sleep due to obstruction of the upper airway. Approximately 35% of patients with OSA have the majority of their events when sleeping on their back, called Positional OSA or POSA. The best available treatment for OSA is Continuous Positive Airway Pressure (CPAP) which is a pump that provides a positive flow of air to keep the airway open. Oral appliances and surgery are also options, but are not as commonly used.
In the case of POSA, therapies that discourage patients sleeping on their back, such as tennis balls and positional belts that place an obstruction to supine sleeping on the patients back, have shown promise. However, patients often struggle to use these devices due to discomfort when they attempt to change position during the night. The device in this study, called SPT avoids this problem by discouraging POSA patients from sleeping on their back by delivering a vibrational stimulus, via a small device which is worn in a chest strap during sleep, each time the patient rolls to their back. This prompts the patient to roll over onto their side. Although several positive studies on the safety and efficacy of the SPT exist, these only focus on patients with mild and moderate disease.
This study aims to assess the long-term safety and effectiveness of the Lunoa SPT for the treatment of POSA.
Who can participate?
Adults with obstructive sleep apnea
What does the study involve?
Participants receive the Lunoa Sleep Position Therapy device for a minimum of two years. They are instructed to use the device nightly. Participants have a follow up appointment once every 12 months, where they undergo a sleep test, complete questionnaires and have the data downloaded from the device to check usage.
What are the possible benefits and risks of participating?
Participants may benefit if the SPT provides effective treatment of their POSA and they are able to use it for longer each night as compared to CPAP. Subjects may also benefit from the increased medical contact during the study period.
There are no additional risks to participating in the study beyond those that would occur if the patient was being treated with the investigational device in routine clinical practice. The SPT is a low risk device.
There is an increased time and cost burden to the patient due to additional visits to the hospital, although the protocol has been designed to include the minimum number of hospital visits within which the research question can be reasonably be answered. Reasonable patients out of pocket expenses are reimbursed by the funder. Sites are required to provide this reimbursement initially and then invoice the funder monthly.
Patients may wish to continue using the SPT following the completion of the study. The funder will sign over the SPT devices of patients who wish to continue and are using this device within its current intended use, to their treating hospital. Patients who wish to continue using the SPT device who are not using it within its current intended will need to wait until the CE mark has been updated after which, the funder will sign over their SPT device to their treating hospital, and the device will be returned to them. The decision as to whether the patient continues with the SPT will be at the discretion of the physician and patient.
Where is the study run from?
1. Antwerp University Hospital (Belgium)
2. OLVG West (Netherlands)
3. Royal Papworth Hospital (UK)
4. Guy’s and St. Thomas’ Hospital (UK)
When is the study starting and how long is it expected to run for?
February 2018 to September 2023
Who is funding the study?
NightBalance B.V (Netherlands)
Who is the main contact?
Prof Olivier Vanderveken (Scientific)
Observational study investigating the long term safety and efficacy of the sleep position trainer in patients with positional obstructive sleep apnea
The primary objective of the study is to assess the long-term safety and efficacy of the Lunoa SPT for the treatment of POSA.
Not provided at time of registration - submission pending
Long-term multi-centre observational study
Primary study design
Secondary study design
Patient information sheet
Not available in web format, please use the contact details below to request a patient information sheet
Positional Sleep Apnea
All participants receive the Lunoa Sleep Position Therapy for a minimum two-year period.
Participants are sent home with instructions to use their device nightly. At baseline and each 12-month interval, participants undergo a polysomnography test, complete a battery of questionnaires, are questioned about the occurrence of adverse events and have their compliance data downloaded from the device.
Primary outcome measure
1. Apnea–Hypopnea (AHI) obtained from a polysomnography (PSG) sleep study at baseline and each 12 month interval.
Secondary outcome measures
1. Efficacy of the device is measured using Epworth Sleepiness Scale (ESS), Pichot Fatigue Scale, Health and Anxiety Scale (HAD) at baseline and each 12 month interval
2. Quality of Life is measured using Functional Outcomes of Sleep Questionnaire (FOSQ) and Short-Form 36 questionnaires (SF-36) at baseline and each 12 month interval
3. Compliance is measured from the device download at each 12 month interval
4. Safety is assessed by recording adverse events (AE) at each 12 month interval
5. Comfort and satisfaction of participant is measured using the Visual Analogue Scale (VAS) at each 12 month interval
Overall trial start date
Overall trial end date
Reason abandoned (if study stopped)
Participant inclusion criteria
1. Adult patients with a diagnosis of supine-dependent OSA defined as;
1.1. an AHI supine ≥ 2x AHI non supine, or,
1.2. AHI non-supine < 10/h and an AHI supine ≥ 10/h,
1.3. and 10 – 90 % supine sleep during PSG.
Target number of participants
Participant exclusion criteria
1. A female of child-bearing potential that is pregnant or intends to become pregnant.
2. Any unstable or severe medical condition of any organ system that at the discretion of the site Principal Investigator (PI) might affect the patient’s participation in the study or generalization of treatment results.
3. Taking medication that at the discretion of the site Principal Investigator (PI) might affect the patient’s participation in the study or generalization of treatment results.
4. Oxygen use
5. The presence of any other sleep disorder (central sleep apnea (CSA >5), periodic limb movement disorder (PLMAI >15), clinical diagnosis of insomnia or narcolepsy)
6. Excessive alcohol consumption (>21 drinks/week)
7. The use of any illegal drug(s), per subject report.
8. Night or rotating shift work.
9. Severe claustrophobia.
10. Shoulder, neck, or back complaints that restrict sleeping position.
11. Subject requires use of more than 2 pillows under the head while sleeping or sleeps in a bed/chair with raised upper body position.
12. Driving risk: any car accident or near miss accident caused by sleepiness in the last 12 months and upon PI discretion
Recruitment start date
Recruitment end date
Countries of recruitment
Belgium, Netherlands, United Kingdom
Trial participating centre
Antwerp University Hospital UZA (PI)
Trial participating centre
1061 AE Amsterdam
Trial participating centre
Royal Papworth Hospital
Trial participating centre
Guy’s and St. Thomas
Funding Body Type
Funding Body Subtype
Results and Publications
Publication and dissemination plan
Planned publication in a high-impact peer-reviewed journal.
IPD sharing statement:
The datasets generated during and/or analysed during the current study are/will be available upon request from Prof Olivier Vanderveken, ENT Head and Neck Surgeon (email@example.com)
Antwerp University Hospital UZA
Faculty of Medicine and Health Sciences
University of Antwerp
Intention to publish date
Participant level data
Available on request
Basic results (scientific)